Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | PDE5A | O76074 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.46 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.46 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8038289 | 1.00 | ALDH1A1 (0.50) | ALDH1A1KDM4EHSD17B10KMT2ASMN1; SMN2 | |
| SCHEMBL8037922 | 1.00 | ALDH1A1 (0.50) | ALDH1A1KDM4EHSD17B10KMT2ASMN1; SMN2 | |
| SCHEMBL8037885 | 0.99 | KMT2A (0.51) | ALDH1A1KDM4EHSD17B10KMT2ASMN1; SMN2 | |
| SCHEMBL8037911 | 0.91 | ALDH1A1 (0.53) | ALDH1A1KDM4EHSD17B10KMT2ASMN1; SMN2 | |
| SCHEMBL6338308 | 0.90 | KMT2A (0.48) | ALDH1A1KDM4EHSD17B10KMT2ASMN1; SMN2 | |
| SCHEMBL6338311 | 0.90 | KMT2A (0.48) | ALDH1A1KDM4EHSD17B10KMT2ASMN1; SMN2 | |
| SCHEMBL6339214 | 0.90 | KMT2A (0.48) | ALDH1A1KDM4EHSD17B10KMT2ASMN1; SMN2 | |
| SCHEMBL8038299 | 0.89 | ALDH1A1 (0.50) | ALDH1A1KDM4EKMT2ASMN1; SMN2GAA | |
| SCHEMBL6405105 | 0.89 | ALDH1A1 (0.50) | ALDH1A1KDM4EKMT2ASMN1; SMN2GAA | |
| SCHEMBL8039539 | 0.89 | ALDH1A1 (0.50) | ALDH1A1KDM4EKMT2ASMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050027008-A1 | Cancer remedy comprising anthranilic acid derivatives as active ingredient | TEIJIN LIMITED | 2005-02-03 | — | — | US | disclosed |
| US-20030220402-A1 | Cancer remedy comprising anthranilic acid derivatives as active ingredients | TEIJIN LIMITED (JP) | 2003-11-27 | — | — | US | disclosed |
| EP-1256341-A1 | CANCER REMEDY COMPRISING ANTHRANILIC ACID DERIVATIVE AS ACTIVE INGREDIENT | TEIJIN LIMITED (JP) | 2002-11-13 | — | — | EP | disclosed |
| EP-0806412-B1 | BENZENE DERIVATIVES | TEIJIN LTD (JP) | 2000-04-05 | — | — | EP | disclosed |
| US-5808144-A | ANTIALLERGENS | TEIJIN LIMITED (JP) | 1998-09-15 | — | — | US | disclosed |
| EP-0806412-A1 | BENZENE DERIVATIVES | TEIJIN LIMITED (JP) | 1997-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220402-A1 | Cancer remedy comprising anthranilic acid derivatives as active ingredients | HCCS, BCOR, CBR1 | ALDH1A1 1126/4885KDM4E 1406/4885HSD17B10 625/4885 |
| US-20050027008-A1 | Cancer remedy comprising anthranilic acid derivatives as active ingredient | CA9, HCCS, CA7 | ALDH1A1 1389/4885KDM4E 1879/4885HSD17B10 335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.